# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
RBC Capital analyst Brian Abrahams reiterates Biogen (NASDAQ:BIIB) with a Outperform and maintains $317 price target.
Biogen Inc. (NASDAQ: BIIB) shares saw a notable uptick Monday afternoon, trading higher after the company revealed a new partne...
Biogen Inc. (NASDAQ:BIIB) and Delta Flight Products (DFP), a wholly-owned subsidiary of Delta Air Lines established to create ...
The European Commission has granted exceptional marketing authorization for Biogen's Qalsody (tofersen), the first EU-appro...
SOD1-ALS is a devastating, uniformly fatal, and ultra-rare genetic form of ALS estimated to affect less than 1,000 people in Eu...
RBC Capital analyst Brian Abrahams reiterates Biogen (NASDAQ:BIIB) with a Outperform and maintains $317 price target.
HC Wainwright & Co. analyst Andrew Fein reiterates Biogen (NASDAQ:BIIB) with a Buy and maintains $300 price target.